ES2270895T3 - Composicion en forma de gel destinada a recibir un principio activo o en suspension, en particular para la aplicacion sobre una mucosa y procedimiento de fabricacion. - Google Patents
Composicion en forma de gel destinada a recibir un principio activo o en suspension, en particular para la aplicacion sobre una mucosa y procedimiento de fabricacion. Download PDFInfo
- Publication number
- ES2270895T3 ES2270895T3 ES00988913T ES00988913T ES2270895T3 ES 2270895 T3 ES2270895 T3 ES 2270895T3 ES 00988913 T ES00988913 T ES 00988913T ES 00988913 T ES00988913 T ES 00988913T ES 2270895 T3 ES2270895 T3 ES 2270895T3
- Authority
- ES
- Spain
- Prior art keywords
- gel
- composition according
- shaped composition
- mucosa
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000000725 suspension Substances 0.000 title claims description 3
- 229920001983 poloxamer Polymers 0.000 claims abstract description 16
- 210000004877 mucosa Anatomy 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 11
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000000227 bioadhesive Substances 0.000 claims abstract description 10
- 229960000502 poloxamer Drugs 0.000 claims abstract description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001631 carbomer Drugs 0.000 claims abstract description 6
- 239000003349 gelling agent Substances 0.000 claims abstract description 3
- 239000013543 active substance Substances 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 239000003433 contraceptive agent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical group C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 3
- 229940124558 contraceptive agent Drugs 0.000 claims description 3
- 229960003913 econazole Drugs 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical class CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- 230000002254 contraceptive effect Effects 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000320 mechanical mixture Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010230 sodium propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 claims 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical group [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 17
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 229940124581 decongestants Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000013008 thixotropic agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9915763A FR2802097B1 (fr) | 1999-12-14 | 1999-12-14 | Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication |
| FR9915763 | 1999-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2270895T3 true ES2270895T3 (es) | 2007-04-16 |
Family
ID=9553244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00988913T Expired - Lifetime ES2270895T3 (es) | 1999-12-14 | 2000-12-14 | Composicion en forma de gel destinada a recibir un principio activo o en suspension, en particular para la aplicacion sobre una mucosa y procedimiento de fabricacion. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030091642A1 (https=) |
| EP (1) | EP1237537B1 (https=) |
| JP (1) | JP2003516957A (https=) |
| AT (1) | ATE336987T1 (https=) |
| AU (1) | AU2525601A (https=) |
| CA (1) | CA2394416A1 (https=) |
| CY (1) | CY1106249T1 (https=) |
| DE (1) | DE60030319T2 (https=) |
| DK (1) | DK1237537T3 (https=) |
| ES (1) | ES2270895T3 (https=) |
| FR (1) | FR2802097B1 (https=) |
| PT (1) | PT1237537E (https=) |
| WO (1) | WO2001043720A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20031640A1 (it) | 2003-08-08 | 2005-02-09 | Mipharm S P A | Base per gel bioadesivi. |
| US20060140990A1 (en) * | 2003-09-19 | 2006-06-29 | Drugtech Corporation | Composition for topical treatment of mixed vaginal infections |
| AU2004274000B2 (en) * | 2003-09-19 | 2009-07-30 | Drugtech Corporation | Pharmaceutical delivery system |
| US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
| CA2605341A1 (en) * | 2005-05-09 | 2006-11-16 | Drugtech Corporation | Modified-release pharmaceutical compositions |
| CN101374501A (zh) * | 2006-01-05 | 2009-02-25 | 药物技术公司 | 组合物及其使用方法 |
| US10045935B2 (en) | 2012-07-31 | 2018-08-14 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252318A (en) * | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| EP0551626A1 (en) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
| JP2533723B2 (ja) * | 1992-12-28 | 1996-09-11 | 東興薬品工業株式会社 | 速乾性ゲルタイプ手指消毒剤 |
| ES2078175B1 (es) * | 1993-12-31 | 1996-10-16 | Cusi Lab | Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones. |
| US5902110A (en) * | 1995-12-18 | 1999-05-11 | The Block Drug Company | Bone regeneration |
| US5869601A (en) * | 1996-04-05 | 1999-02-09 | S. C. Johnson & Son, Inc. | Method of stabilizing the viscosity of a thickened composition |
| EP1011609A4 (en) * | 1997-05-09 | 2000-08-16 | Medlogic Global Corp | COMPOSITIONS FOR COSMETIC APPLICATIONS |
| US7064114B2 (en) * | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
-
1999
- 1999-12-14 FR FR9915763A patent/FR2802097B1/fr not_active Expired - Fee Related
-
2000
- 2000-12-14 ES ES00988913T patent/ES2270895T3/es not_active Expired - Lifetime
- 2000-12-14 WO PCT/FR2000/003533 patent/WO2001043720A1/fr not_active Ceased
- 2000-12-14 DE DE60030319T patent/DE60030319T2/de not_active Expired - Lifetime
- 2000-12-14 DK DK00988913T patent/DK1237537T3/da active
- 2000-12-14 AT AT00988913T patent/ATE336987T1/de active
- 2000-12-14 JP JP2001544659A patent/JP2003516957A/ja active Pending
- 2000-12-14 EP EP00988913A patent/EP1237537B1/fr not_active Expired - Lifetime
- 2000-12-14 CA CA002394416A patent/CA2394416A1/fr not_active Abandoned
- 2000-12-14 US US10/149,695 patent/US20030091642A1/en not_active Abandoned
- 2000-12-14 PT PT00988913T patent/PT1237537E/pt unknown
- 2000-12-14 AU AU25256/01A patent/AU2525601A/en not_active Abandoned
-
2006
- 2006-11-16 CY CY20061101679T patent/CY1106249T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2394416A1 (fr) | 2001-06-21 |
| PT1237537E (pt) | 2007-01-31 |
| DE60030319T2 (de) | 2007-08-30 |
| EP1237537B1 (fr) | 2006-08-23 |
| FR2802097B1 (fr) | 2002-12-13 |
| ATE336987T1 (de) | 2006-09-15 |
| FR2802097A1 (fr) | 2001-06-15 |
| DK1237537T3 (da) | 2006-12-27 |
| AU2525601A (en) | 2001-06-25 |
| JP2003516957A (ja) | 2003-05-20 |
| EP1237537A1 (fr) | 2002-09-11 |
| US20030091642A1 (en) | 2003-05-15 |
| WO2001043720A1 (fr) | 2001-06-21 |
| CY1106249T1 (el) | 2011-06-08 |
| DE60030319D1 (de) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6591536B2 (ja) | 特定の投薬量の活性物質を皮膚又は粘膜に投与するための電気流体力学的に得られた繊維を含む組成物 | |
| ES2308045T3 (es) | Composiciones fungicidas, lubricantes de calentamiento y no irritantes en la forma de un gel. | |
| KR101792200B1 (ko) | 열감응성 겔 마취제 조성물 | |
| KR101809713B1 (ko) | 방부제 없는 프로스타글란딘계 비점성 용액의 고분자 전달 시스템 | |
| ES2336238T3 (es) | Agentes anti-disritmicos administrados por via vaginal para tratar la disritmia uterina. | |
| Sahoo et al. | Intra vaginal drug delivery system: an overview | |
| JP2002514220A (ja) | 熱傷処置および感染防止のための局部スプレー | |
| ES2259806T3 (es) | Composicion farmaceutica para tratar la incontinencia fecal y el prurito anal. | |
| US20040043071A1 (en) | Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs | |
| RU2560879C2 (ru) | Cпособ профилактики передающихся половым путем вирусных заболеваний, лекарственное средство, способ получения лекарственного средства, фармацевтическая композиция для местного применения и презерватив | |
| HU220864B1 (en) | Reversible, thermally gelling water-base medicinal compositions | |
| US12336979B2 (en) | Material and method for treating cancer | |
| ES2221127T3 (es) | Uso de acitromicina en el tratamiento topico de infecciones oculares. | |
| Priyanka et al. | Review on formulation and evaluation of solid lipid nanoparticles for vaginal application | |
| ES2270895T3 (es) | Composicion en forma de gel destinada a recibir un principio activo o en suspension, en particular para la aplicacion sobre una mucosa y procedimiento de fabricacion. | |
| CN104338147B (zh) | 一种用于缓控释给药的软膏组合基质 | |
| Bharat et al. | A review: Novel advances in semisolid dosage forms & patented technology in semisolid dosage forms | |
| WO2019161470A1 (pt) | Composição farmacêutica na forma de suspensão aquosa e uso de uma composição farmacêutica na forma de suspensão aquosa | |
| BRPI0616449A2 (pt) | composição oftálmica, preparação combinada, uso da referida composição e uso de um agente formador de pelìcula | |
| US20240074973A1 (en) | Pharmaceutical composition for topical administration containing epi-nastine or salt thereof | |
| CN101163486B (zh) | 阿奇霉素在生产用于治疗眼部感染的药物中的用途 | |
| ES2618300T3 (es) | Composiciones farmacéuticas de liberación controlada y prolongada que comprenden polímeros cargados | |
| Khajeamiri et al. | Vaginal Novel Drug Delivery Systems | |
| RU2093146C1 (ru) | Жидкая самовспенивающаяся фармацевтическая композиция | |
| Ghule et al. | THE ROLE OF GEL FORMULATIONS IN ADVANCING TOPICAL DRUG DELIVERY SYSTEMS |